NCT02420873View on ClinicalTrials.gov

An Open-label Phase II Study of Lorvotuzumab Mertansine

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

May 12, 2015

Primary Completion Date

June 6, 2017

Study Completion Date

June 6, 2017

Conditions

Leukemia

Interventions

DRUG

Lorvotuzumab Mertansine (IMGN901)

100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

ImmunoGen, Inc.

All Listed Sponsors

collaborator

ImmunoGen, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02420873 - An Open-label Phase II Study of Lorvotuzumab Mertansine | Biotech Hunter | Biotech Hunter